Contineum Therapeutics (CTNM) Net Cash Flow (2023 - 2026)

Contineum Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at -$5.4 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 223.07% year-over-year to -$5.4 million; the TTM figure through Jun 2026 stood at -$6.1 million (up 89.24% YoY), while the FY2025 annual figure was $53.7 million, up 736.22% from the prior year.
• Net Cash Flow for Q2 2026 stood at -$5.4 million, up from -$55.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $61.0 million in Q2 2024, with the low at -$55.4 million in Q1 2026.
• The 4-year median for Net Cash Flow is -$579500.0 (2025), against an average of $653000.0.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 274.0% in 2025, then tumbled 10620.87% in 2026.
• Contineum Therapeutics' Net Cash Flow stood at -$2.0 million in 2023, then sank by 849.77% to -$18.9 million in 2024, then jumped by 274.0% to $33.0 million in 2025, then sank by 116.52% to -$5.4 million in 2026.
• Business Quant data shows CTNM's Net Cash Flow at -$5.4 million in Q2 2026, -$55.4 million in Q1 2026, and $33.0 million in Q4 2025.